Progressive supranuclear palsy syndrome induced by clebopride

Movement Disorders

Volumn 19, Issue 4, 2004, Pages 482-484

  Campdelacreu, Jaume ^a   Kumru, Hatice ^a   Tolosa, Eduard ^a   Valls Solé, Josep ^a   Benabarre, Antoni ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Clebopride; Drug induced parkinsonism; Progressive supranuclear palsy

Indexed keywords

CLEBOPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; FLATORIL; PROKINETIC AGENT;

ADULT; AKATHISIA; ARTICLE; BLEPHAROSPASM; CASE REPORT; CLINICAL FEATURE; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GENETIC ANALYSIS; HUMAN; NEUROLOGIC EXAMINATION; NEUROPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TARDIVE DYSKINESIA;

ANTIEMETICS; BENZAMIDES; FEMALE; HUMANS; MIDDLE AGED; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 2342432883     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10692     Document Type: Article

References (25)

1. Tolosa E, Valldeoriola F, Marti MJ. Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). J Neural Transm Suppl 1994;42:15-31.
2. de Bruin VM, Lees AJ, Daniel SE. Diffuse Lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: a case report. Mov Disord 1992;7:355-358.
3. Shiozawa M, Fukutani Y, Sasaki K, et al. Corticobasal degeneration: an autopsy case clinically diagnosed as progressive supranuclear palsy. Clin Neuropathol 2000;19:192-199.
4. Shimamura M, Uyama E, Hirano T, Murakami T, Mita S, Kitamoto T, Uchino M. A unique case of sporadic Creutzfeldt-Jakob disease presenting as progressive supranuclear palsy. Intern Med 2003;42:195-198.
5. Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl 1994;42:189-201.
6. Tolosa E, Valldeoriola F. Progressive supranuclear palsy. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins; 1998. p 221-243.
7. Riley D. Secondary parkinsonism. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins; 1998. p 317-339.
8. Aguilar M, Valles V, Garolera M, Delgado L, Alberni J. Drug induced progressive supranuclear palsy (PSP) syndrome. Mov Disord 1996;11:142.
9. Montagna P, Gabellini AS, Monari L, Lugaresi E. Parkinsonian syndrome after long-term treatment with clebopride. Mov Disord 1992;7:89-90.
10. Jimenez-Jimenez FJ, Cabrera-Valdivia F, Ayuso-Peralta L, Tejeiro J, Vaquero A, Garcia-Albea E. Persistent parkinsonism and tardive dyskinesia induced by clebopride. Mov Disord 1993;8:246-247.
11. Martinez-Martin P. Transient dyskinesia induced by clebopride. Mov Disord 1993;8:125-126.
12. Sempere AP, Duarte J, Palomares JM, Coria F, Claveria LE. Parkinsonism and tardive dyskinesia after chronic use of clebopride. Mov Disord 1994;9:114-115.
13. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
14. Vidailhet M, Rothwell JC, Thompson PD, Lees AJ, Marsden CD. The auditory startle response in the Steele-Richardson-Olszewsky syndrome and Parkinson's disease. Brain 1991;115:1181-1192.
15. Valls-Solé J, Valldeoriola F, Tolosa E, Martí MJ. Distinctive abnormalities of facial reflexes in patients with PSP. Brain 1997;120:1877-1883.
16. Pierrot-Deseilligny C, Rivaud S, Pillon B, Fournier E, Agid Y. Lateral visually-guided saccades in progressive supranuclear palsy. Brain 1989;112:471-487.
17. Pastor P, Ezquerra M, Tolosa E, et al. Further extension of the H1 haplotype associated with progressive supranuclear palsy. Mov Disord 2002;17:550-556.
18. Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J Pharm Pharmacol 1988;40:415-421.
19. Serrano Serrano ME, Alvarez Frejo M, Tabernero Garcia J, Martin Martin S. An extrapyramidal syndrome due to clebopride. Aten Primaria (Spanish) 1999;23:50-51.
20. Bavestrello L, Caimi L, Barbera A. A double-blind comparison of clebopride and placebo in dyspepsia secondary to delayed gastric emptying. Clin Ther 1985;7:468-473.
21. Kluin KJ, Foster NL, Berent S, Gilman S. Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology 1993;43:563-566.
22. Valls-Solé J, Valldeoriola F, Cossu G. Exámenes neurofisiológicos en el síndrome parkinsoniano. Neurologia (Spanish) 1999;14:289-305.
23. Martí-Massó JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998;13:453-456.
24. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-1083.
25. Wilson JA, Primrose WR. Drug induced parkinsonism. BMJ 1986; 293:957.